patent.fyi
Applications  /  US 2026/0356882
United States Patent Application Publication

US 2026/0356882 A1

Published
Nov 12, 2026
Filed
Oct 10, 2023
Earliest date on the face
Oct 10, 2022
Classification
C07K 1/1077
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Thiol coupling on silica

What ifWhat if a silica nanocarrier presents surface thiols through a silane coating?
Claim language“a modified lipid”

A mercaptosilane forms a thiol-bearing coating on colloidal silica. A reporter protein bearing a maleimide group reacts with the surface thiols to form thioether bonds.

1.1Calcium phosphate surface binding

What ifWhat if a calcium phosphate nanocarrier binds the functional protein through its mineral surface?
Claim language“a modified lipid”

Calcium and phosphate salts precipitate as hydroxyapatite nanoparticles in water. A polyaspartate segment fused to a reporter enzyme binds exposed calcium sites and holds the enzyme at the particle surface.

1.2Protein production in yeast

What ifWhat if intact yeast cells produce the fusion protein for a separate nanocarrier coupling step?
Claim language“a cell-free protein synthesis system”

Yeast cells express a reporter enzyme fused to a peptide bearing an exposed cysteine. After purification, the cysteine reacts with maleimide groups on assembled vesicles to form thioether bonds.

1.2Coupling after protein purification

What ifWhat if the assembled nanocarrier contacts the purified fusion protein only after the cell-free synthesis mixture is removed?
Claim language“incubating the assembled nanocarrier with a cell-free protein synthesis system”

A cell-free reaction produces a reporter enzyme fused to a peptide bearing an exposed cysteine. Affinity chromatography and buffer exchange separate the fusion protein from the synthesis mixture before maleimide-bearing vesicles are added.

1.3Purified fusion protein feedstock

What ifWhat if a purified fusion protein serves as the feedstock for the nanocarrier coupling reaction?
Claim language“a nucleic acid template encoding a fusion protein”

The coupling vessel receives maleimide-bearing vesicles and a purified reporter enzyme fused to a peptide bearing an exposed cysteine. The cysteine forms a thioether bond with a surface maleimide, and size-exclusion chromatography removes free enzyme.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Particle-bound laccase for water analysis

Silica nanoparticles carry a supported lipid bilayer containing nickel-chelating lipids. An oxidative cell-free protein synthesis mixture expresses a bacterial laccase fused to a hexahistidine tag, which binds the nickel-chelating lipids during incubation. Centrifugation and resuspension remove soluble reaction components, and the washed particles oxidize a phenolic reporter to produce a visible absorbance signal for a water-quality assay.

Component substitution

Covalent attachment through a terminal cysteine

Supported lipid nanoparticles incorporate a phospholipid with a maleimide group at the end of a polyethylene glycol spacer. A cell-free mixture expresses a cysteine-free fluorescent reporter fused to a short peptide with a single C-terminal cysteine. Spin desalting transfers the translation mixture into a thiol-free buffer at pH 6.8 before particle addition, and the exposed cysteine forms a thioether bond with the maleimide. Size-exclusion chromatography separates the conjugated particles from soluble protein.

Planar lipid nanodiscs as protein carriers

Amphipathic scaffold proteins assemble phosphatidylcholine and a nickel-chelating phospholipid into discoidal bilayer particles. Detergent removal drives assembly, and size-exclusion chromatography isolates the discs before they enter a cell-free synthesis mixture containing the template for a hexahistidine-tagged fluorescent reporter. The reporter binds lipid headgroups exposed on both faces of the discs during incubation. A second size-exclusion step collects the fluorescent disc fraction separately from unbound reporter.

Parameter or scale variation

Parallel synthesis across lipid anchor densities

Three batches of 100 nm silica cores receive supported bilayers containing 0.25, 1.0, or 4.0 mol% nickel-chelating lipid, with phosphatidylcholine making up the balance. Each 50 microliter reaction contains the same particle concentration, a cell-free protein synthesis mixture, and a template encoding a hexahistidine-tagged fluorescent reporter. After 60 minutes at 30 °C, centrifugation and washing recover the particles. Fluorescence normalized to recovered silica mass measures reporter loading across the three anchor densities.

Automated or data-driven variant

Robotic screening of surface enzyme loading

A liquid handler dispenses lipid-coated magnetic nanoparticles, cell-free synthesis mix, and a template encoding hexahistidine-tagged alkaline phosphatase into a multiwell plate. The software varies template concentration and incubation time while holding particle concentration constant. After incubation, a magnetic plate captures the particles for automated washing, and a plate reader measures the rate of color formation from a phosphatase substrate. The software subtracts the signal from wells without template and ranks the conditions by activity per mass of particles dispensed.

Specific version of a part

Maleimide groups on vesicles

A phosphatidylcholine mixture contains a small mole fraction of a phospholipid bearing a maleimide at the end of a polyethylene glycol spacer. Hydration and extrusion form vesicles with solvent-accessible maleimide groups on the outer surface.

Incubation in bacterial extract

Assembled vesicles are mixed with a clarified bacterial extract, amino acids, nucleotide triphosphates, and an energy regeneration mixture. The vesicles remain in the reaction while the extract produces the tagged reporter enzyme.

Messenger RNA fusion template

A purified messenger RNA contains a ribosome-binding site and a continuous coding sequence for a reporter enzyme, a flexible peptide linker, and a cysteine-bearing tag. Translation releases a single polypeptide whose exposed tag cysteine reacts with a maleimide on the modified lipid.

Peptide directed isopeptide coupling

The template encodes a reporter enzyme fused to a short peptide bearing a reactive aspartate. A complementary protein domain is tethered to the lipid headgroup and forms an isopeptide bond between one of its lysines and the peptide’s aspartate.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2019/0309015 A1
Published
Oct 10, 2019
Filed
Apr 8, 2019
Class
C07K 1/22
Document BUS 10,842,746 B1
Published
Nov 24, 2020
Filed
Aug 24, 2017
Class
A61K 9/1271
Claim 1
Document A
Document B
1.1assembling the nanocarrier with a modified lipid;
Liposomes were prepared composed of the phospholipid POPC, cholesterol, and a phospholipid containing a Ni-NTA head group, and were extruded through a filter to achieve a defined size (1 μm diameter), and freeze-dried.
A · US 2019/0309015 A1 · ¶ 75
The methods include the steps of: providing a lipid composition comprising a plurality of reactive lipids, wherein each of the reactive lipids comprises a reactive hydrophobic group, a reactive hydrophilic group, or a reactive hydrophilic group and a reactive hydrophobic group; forming an un-crosslinked liposome comprising the reactive lipids; and crosslinking at least a portion of the reactive hydrophobic groups or the reactive hydrophilic groups; thereby producing the bi-di
B · US 10,842,746 B1 · abstract
1.2incubating the assembled nanocarrier with a cell-free protein synthesis system and
The cell free extract containing the expression system components, nucleic acid encoding the protein of interest (with the necessary liposome-binding means) and the liposomes (with the protein binding means) may be mixed together; once sufficient protein is generated and binds to the liposomes, the protein-decorated liposomes can be pelleted by centrifugation and washed to remove other materials from the reaction matrix.
A · US 2019/0309015 A1 · ¶ 43
1.3a nucleic acid template encoding a fusion protein, the fusion protein comprising: a protein tag that conjugates to the modified lipid; and the functional protein.
In one embodiment the moiety is a sequence of amino acids fused into the nucleic acid encoding the protein of interest, such that when the protein is expressed the liposome-binding moiety is expressed in the protein. In one embodiment, the sequence of amino acids is a series of six histidines, known in the art as a His tag, His6 tag, or 6×His tag, which sequence binds non-covalently to nickel atom chelated by a nitrilotriacetic acid (NTA) moiety on the liposome.
A · US 2019/0309015 A1 · ¶ 52

An empty cell means only that no passage was reproduced there.

Statements in these documents
However, this complex mixture is unsuitable for clinical use and the vaccine or protein of interest must first be purified.
A · US 2019/0309015 A1 · ¶ 2
It is towards the facile purification of proteins from Tx/TL or any other protein production systems that the present invention is directed.
A · US 2019/0309015 A1 · ¶ 3
As a result, it is difficult to tune the release rate of liposomes bearing encapsulated hydrophobic loads, as well as to generate liposomal systems that are resistant to serum protein penetration and other destabilizing forces encountered in vivo.
B · US 10,842,746 B1 · ¶ 2
Accordingly, new methods for production of stabilized liposomes are needed in order to provide improved nanocarriers for therapeutic agents and diagnostic agents.
B · US 10,842,746 B1 · ¶ 3
Cite aspatent.fyi, US 2026/0356882 A1, claim 1, first published 2026-11-20T08:53:13-05:00, https://patent.fyi/US20260356882/, SHA-256 9f2535e01363fdee11029b57571d2258f7112341dab7a86fa97803df0b7df7d6
First published
Permanent addresshttps://patent.fyi/US20260356882/
Content fingerprint (SHA-256)9f2535e01363fdee11029b57571d2258f7112341dab7a86fa97803df0b7df7d6
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi